EICHOR
● Active Not Recruiting
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Condition: Extensive Stage Small Cell Lung Cancer · Sponsor: Novartis Pharmaceuticals
About this study
This study aims to establish a safe and well tolerated dose of \[177Lu\]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in this setting and to assess preliminary efficacy of this combination treatment versus the combination of carboplatin, etoposide, and atezolizumab.The study will be essential to assess a new potential therapeutic option in participants with this aggressive cancer type.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (30)
| Georgetown University Lombardi Cancer Center | Washington D.C., District of Columbia, United States | — |
| AdventHealth | Orlando, Florida, United States | — |
| University Cancer and Blood Center LLC | Athens, Georgia, United States | — |
| University of Kentucky | Lexington, Kentucky, United States | — |
| St Louis University | St Louis, Missouri, United States | — |
| Hackensack University Medical Ctr | Hackensack, New Jersey, United States | — |
| University Hospitals Of Cleveland | Cleveland, Ohio, United States | — |
| Fox Chase Cancer Center | Philadelphia, Pennsylvania, United States | — |
| Novartis Investigative Site | Linz, Upper Austria, Austria | — |
| Novartis Investigative Site | Vienna, Austria | — |
| Novartis Investigative Site | Montreal, Quebec, Canada | — |
| Novartis Investigative Site | Beijing, China | — |
+ 18 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05142696